Hospital M&A activity has been increasing recently, and when these transactions are public knowledge, opposition from the physician community (as well as the hospital staff) to such types of transactions may also be a side effect. Physicians are vital to the operation of a hospital, and any resistance from the physician community, could be a tremendous obstacle, either slowing down the transaction or causing the potential buyer to pull out of the deal. Hospital administrators, along with their advisors, should do their best to foresee any opposition and manage physicians ...
While I may be stating the obvious, hospitals and health systems are complex creatures that frequently drive local economies, culture and population health status (among other things). Accordingly, when considering a potential change of control transaction, it is critical that you examine what drives your organization and what [in the community] your organization drives. In particular, the latter is frequently overlooked in these circumstances.
What Drives Your Organization (Your Mission)
So, how do you begin to identify your organization's priorities? I recommend ...
Organizations considering a significant transaction have a lot to think about. One of the most important is making certain that relationships with key constituents and stakeholders are appropriately maintained and managed. Too frequently, community hospitals and community health systems underestimate the scope and importance of those relationships.
Most of us can rattle-off a short list of key constituents and stakeholders for community hospitals and community health systems.
Here's my standard list, together with a short description of why they are important:
- Board ...
Blog Editors
Recent Updates
- Important Negotiating Points in Commercial Real Estate Purchase and Sale Contracts Negotiating the Letter of Intent
- 2025 Picks Up Steam with Increased Scrutiny of Health Care Transactions and Corporate Structures
- HHS Reverses Its Longstanding Policy and Limits Public Participation in Rulemaking
- Sitting Atop a Telehealth Cliff?
- A Regulatory Haze of Uncertainty Continues as the Clock Ticks Toward Phase One of FDA’s LDT Final Rule